Does Arizona Medicaid (AHCCCS) Cover Ozempic, Wegovy or Zepbound?

Arizona Medicaid, called AHCCCS, covers Ozempic only for type 2 diabetes, and in its fee-for-service program Ozempic is a non-preferred drug that needs failed 90-day trials of Trulicity, Victoza or generic liraglutide, and Mounjaro first.^[1] As of November 2026 no GLP-1 is covered for weight loss, Zepbound for sleep apnea is refused as a plan exclusion, and Wegovy is approved only for heart-risk reduction or the liver disease MASH.^[1][2][4]

Does AHCCCS cover Ozempic?

Yes, for type 2 diabetes, which is the use on its label.^[9] What surprises many people is the order. Since October 1, 2026 the preferred GLP-1s in fee-for-service are Mounjaro, Trulicity, brand Victoza and generic liraglutide; Ozempic and exenatide are non-preferred.^[1][14] The change log for that date reads “Mounjaro to PDL, Exenatide to NPD.”^[14] A November 1, 2026 revision kept that order and tightened the paperwork: the A1C lab report must now be submitted, the 90-day metformin trial must show up in paid pharmacy claims, and the request must confirm the drug will not be taken with another GLP-1.^[1]

Two practical points follow. Mounjaro and Zepbound contain the same medicine, tirzepatide, so a person with diabetes is better placed asking for Mounjaro, now a preferred drug, than for Ozempic.^[10] And the pill route has its own door for people who cannot inject because of a physical or visual impairment, skin changes at injection sites or a documented needle phobia.^[1] The AHCCCS drug list has no semaglutide row at all, and its header says drugs left off the list may still be available through prior authorization.^[3]

Does AHCCCS cover Wegovy or Zepbound for weight loss?

No. The fee-for-service billing manual lists “medications used for weight loss treatment” among its pharmacy exclusions, and the Wegovy criteria tell reviewers to deny a weight-loss request “as a benefit exclusion.”^[4][2] The diabetes criteria add the same test for every GLP-1: the drug must not be used for weight loss.^[1] Under federal law, a state may leave weight-loss drugs out of Medicaid, and our explainer on why Medicaid treats Ozempic and Wegovy differently covers that choice.^[8]

The exclusion is written broadly. Unlike states that treat sleep apnea as a separate medical use, Arizona’s criteria tell reviewers to deny drugs that “improve conditions caused by obesity,” with Zepbound for sleep apnea as the named example.^[1] The FDA approved Zepbound for moderate to severe sleep apnea in adults with obesity, so the refusal reflects Arizona’s benefit design rather than any doubt about the drug.^[10] See Zepbound for sleep apnea for the trial data.

Will AHCCCS cover Wegovy for heart disease?

Yes, with prior authorization, but the test is stricter than the label in three ways.^[2][11] The patient must be 45 or older, the BMI must be 30 or more, and the heart history must come from a short list: a prior heart attack, or a code for an old heart attack, cardiac arrest, a pacemaker, bypass surgery, a replaced heart valve or a coronary stent or graft.^[2] A past stroke or peripheral artery disease on its own is not on that list, even though the label’s heart use covers adults with established cardiovascular disease more generally.^[2][11]

• After a heart attack: records or claims showing the patient takes a cholesterol drug, a beta blocker, an ACE inhibitor or ARB or ARNI, and an antiplatelet drug, or cannot take any of them.^[2]
• Exclusions: diabetes or an A1C of 6.5% or more, class IV heart failure, or end-stage kidney disease.^[2]
• Approval length: six months at a time, and each renewal again needs a BMI of 30 or more.^[2]

The diabetes exclusion means someone with diabetes and heart disease goes through the diabetes criteria instead, where the preferred drugs come first.^[1][2]

Does AHCCCS cover Wegovy for fatty liver disease (MASH)?

Yes, since a January 28, 2026 revision added the use.^[2] The request covers the Wegovy injection for adults with MASH and fibrosis at stage F2 or F3, with no cirrhosis.^[2] The stage must be confirmed by one of the named tests: an ELF blood test, FibroScan or another vibration-controlled liver stiffness scan, the FAST or MAST scores, MRI elastography combined with a FIB-4 score, or a liver biopsy within the past 12 months.^[2] A gastroenterologist, hepatologist or endocrinologist must prescribe or consult, and the drug cannot be combined with another GLP-1 or with Rezdiffra.^[2]

The first approval lasts six months; renewals run 12 months and need evidence the liver is responding, such as better liver tests or imaging.^[2] The label approval for MASH is an accelerated one, and our page on GLP-1s and MASH explains what that means.^[11]

Do AHCCCS health plans follow the same rules?

Not necessarily word for word. AHCCCS lists separate pharmacy managers by plan: OptumRx for fee-for-service and UnitedHealthcare Community Plan, Express Scripts for Banner University Family Care, Arizona Complete Health and Care1st, and CVS Caremark for Mercy Care, Health Choice Arizona and Molina.^[5] Each plan applies its own prior authorization forms, so call the number on your member card and ask for the plan’s Wegovy or GLP-1 criteria before filing. Our guide to why Medicaid plans and fee-for-service differ explains the split.

For fee-for-service members, prescribers fax the OptumRx prior authorization form to 866-463-4838; the OptumRx help desk is (855) 577-6310.^[4]

How do you appeal an AHCCCS denial?

Health plan members file the first appeal with the plan, orally or in writing, within 60 days of the notice.^[6] If the plan’s answer goes against you, federal rules give at least 90 and at most 120 days from that decision to ask for a state fair hearing, so use the deadline printed on the plan’s notice.^[7]

An appeal has the most room when the dispute is about evidence: a missing fibrosis test, chart notes for a prior heart attack, or proof of the earlier diabetes drugs. It has little to work with for weight loss or sleep apnea, which the criteria exclude by design.^[1][4] Our walkthrough of prior authorization and appeals covers what to send, and the Arizona state page collects the Medicaid facts in brief.

What are the options if AHCCCS will not pay?

Cash is the main one, since Lilly’s savings card terms exclude anyone enrolled in Medicaid.^[12] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses through Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound.^[12][13] Read each offer’s rules on government coverage first. Our list of the cheapest GLP-1 routes without insurance compares them.